title: Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
authors: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors: M S
authors: MS
authors: Zabriskie
authors: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors: N A
authors: NA
authors: Vellore
authors: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors: K C
authors: KC
authors: Gantz
authors: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.|Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
authors: M W
authors: MW
authors: Deininger
authors: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.|Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
authors: T
authors: T
authors: O'Hare
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D009154:Mutation; D054730:Protein Interaction Domains and Motifs / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl